The Inception of Glytec

Like many great innovations, Glytec was born from the combination of two very different realms of expertise.

Robby Booth was a software developer in 2005 when he was introduced to Dr. Bruce Bode, a diabetologist renowned for his pioneering work in glucose sensing and insulin delivery. Bode’s early work made advancements through the “paper-protocol” that he published, and generously shared with the world for free, making it widely used by hospitals and current software competitors. These efforts continue to shape the landscape of diabetes care, extending far beyond his family’s 100-year legacy.

+ Read full story

But in terms of clinical sophistication and outcomes, the “paper protocol” was a small step. Recognizing the enormity of the opportunity before them, Booth and Bode created Glytec to take a giant leap forward. Their collaboration, enriched by years of dedicated research and immersive study in Dr. Bode’s diabetes clinic, led to the development of the first FDA-cleared software and algorithms for glucose management in 2006. This seminal innovation, since improved and validated by over 100 patents and over 100 publications, offers a more sophisticated, safe, and effective solution tailored for the needs of modern healthcare.

This groundbreaking achievement has not only impacted millions of lives and saved billions in healthcare costs but also revolutionized a critical care area affecting 40% of hospital patients and the top three medication related events occurring in hospitals nationwide, significantly enhancing the outcomes produced by nurses and healthcare providers.

Glytec continues to serve as leading advocates for patient safety and healthcare modernization, most recently supporting the CMS proposed rule reform and enhanced diabetes management which states that Glycemic (Hyper and Hypo) measures are mandatory beginning in 2026. Our goal is simple: that every hospital has the tools to achieve diabetes excellence in their hospitals that has been validated by FDA. While there is still work to be done, we are proud to be at the forefront of advancing glucose and diabetes care beyond the outdated protocols of the past, and we invite you to be part of this exciting mission to transform diabetes technology and care.

Glytec’s Innovations in Diabetes and Insulin Management

2026

Acute care hospitals required to begin reporting of severe hypoglycemia and hyperglycemia performance metrics to CMS as part of Inpatient Quality Reporting.

Glytec’s eGMS technology reduces hypoglycemia and improves patient outcomes.

Continued focus on AI-based technology and personalized diabetes and insulin treatment.

2024

Glytec and Major Health Partners (MHP) Forge Strategic Partnership to drive continued improvement in patient care and diabetes management.

Glytec Joins Leapfrog’s Partner Advisory Committee to Enhance Patient Safety and Elevate Inpatient Diabetes Care.

Glytec Announces New Analytics Platform – Unveils Real-Time Analytics to Help Hospitals Prepare for New CMS Measures.

Glytec Launches New its new website, Glytec.com, to provide comprehensive information about its industry-leading SaaS platform for diabetes management and insulin dosing.

Glytec and University Hospitals (UH) Forge Strategic Partnership: Partnership to drive continued improvement in patient care and diabetes management.

Glytec Announces Support for Landmark New CMS Measures to Improve Diabetes Reporting – Announces Advocacy Program “Championing Change.

Glytec Expands Executive Team to Drive Innovation and Growth – Announces Patrick F. Cua as Chief Executive Officer.

2023

Glytec unveils latest version of Glucommander insulin dosing software – making it easier for providers, nurses, and pharmacists to offer optimal, personalized care.

2022

Glytec and CPS Solutions, LLC (CPS), a leading provider of enterprise pharmacy solutions to hospitals and health systems integrate to Provide Evidence-Based Glycemic Management.

Glytec Achieves HITRUST CSF® Certification to Manage Risk, Improve Security Posture and Meet Compliance Requirements.

Glytec Secures 100th Patent.

Glytec and Roche strike collaboration on insulin management diagnostics on handheld point-of-care devices.

2021

Glytec Awarded First Patient Safety Solutions Agreement with Premier.

Glytec Appoints Dr. Jordan Messler as Chief Medical Officer.

Glytec Raises $21 Million in financing from Silicon Valley Bank (SVB), Savitr Capital and other private investors.

FDA granted entrance to FDA Safter Technologies Program, intended to accelerate regulatory review and time to market for products expected to significantly improve the benefit-risk profile of a treatment or diagnostic.

Glytec launches latest version of its eGlycemic Management System (eGMS) for managing insulin centered around the FDA-cleared Glucommander algorithm.

2020

Glytec Publishes First COVID-19 Research to Study the ‘Opportunity Window’ for Treating Hospitalized Patients with Diabetes or Hyperglycemia.

2019

Glytec Goes Global, With Six New International Patent Allowances, gaining worldwide protections for its proprietary diabetes therapy management solutions.

2018

Glytec serves over 100,000 patients.

2017

Glytec Announces Fourth FDA 510(k) Clearance for Its Market-Leading Diabetes Therapy Management Software.

2012

Glytec files first patent application.

Glytec Achieves ISO 13485 certification, as the first company to achieve this medical device certification in the glycemic management product space.

Glucommander System FDA cleared for pediatric use.

2010

Glytec receives FDA clearance for Glucommander SubQ.

2006

Glytec develops first FDA-cleared software and algorithms, Glucommander for glucose management and gets patients into target range faster with fewer insulin-related adverse drug events than patients treated with other methodologies.

On a mission to change Healthcare for Diabetes and Insulin Management Dr. Bode and Robby Booth establish Glytec.

2005

FDA approves intravenous insulin titration for pediatric patients.

Book a Discussion

See how your manual glycemic workflows are creating avoidable risk.

BOOK A BRIEF MEETING